---
title: "Obefazimod (ABX464) in Ulcerative colitis: Incidence"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Incidence. Topics: United States: 6.3 per 100,000 person-years in pooled commercial, Medicare, and Medicaid claims; United States: age at onset; Global: highest incidence in Scandinavia, with a ceiling of about 40 per 100,000; Global: rising incidence in newly industrialized regions of Asia; 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/incidence"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of Ulcerative colitis

<a id="topic-2.2.1.2.1-1"></a>

### United States: 6.3 per 100,000 person-years in pooled commercial, Medicare, and Medicaid claims

> “Overall, the incidence of ulcerative colitis (6.3, 95% CI 6.1–6.6) was higher than that of Crohn’s disease (4.1, 95% CI 3.9–4.3).”
> “The incidence of IBD, ulcerative colitis and Crohn’s disease peaked in the third decade of life, decreased to a stable relatively stable level across the 4th to 8th decades, and declined further beyond age 80.”
> “However, among children, the incidence of Crohn’s disease was higher than ulcerative colitis (Figure 1, Supplemental Table 1).”

Source: [Lewis et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10592313/)

<a id="topic-2.2.1.2.1-2"></a>

### United States: age at onset

> “The condition may present at any time and at all ages, but there is a predominant age distribution of onset that peaks in the third decade of life.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

> “Most individuals are diagnosed between the ages of 15 and 35.”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-2.2.1.2.1-3"></a>

### Global: highest incidence in Scandinavia, with a ceiling of about 40 per 100,000

> “The highest incidence of IBD, particularly UC, has been reported in Scandinavia (Fig. 1a,b).”
> “In Denmark, incidence steadily increased from the 1970s (CR-I: 2.05–3.55 for CD; 6.50–9.12 for UC) to 1990s (CR-I: 7.30–10.68 for CD; 13.18–20.99 for UC) and to 2010s (CR-I: 12.62–15.84 for CD; 22.21–30.64 for UC)”
> “The highest ever reported UC incidence was 73.7 in the Faroe Islands in 2011”
> “Thus, 40 per 100,000 serves as a ceiling threshold for the incidence of CD or UC.”

Source: [Hracs et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12158780/)

<a id="topic-2.2.1.2.1-4"></a>

### Global: rising incidence in newly industrialized regions of Asia

> “By 2000, the incidence had increased tenfold reaching 4.77 and 1.27 for UC and CD, respectively (Supplementary Fig. 9a).”
> “South Korea showed similar patterns, with low incidence in the 1980s (CR-I: 0–0.03 for CD; 0.21–0.33 for UC) increasing steadily into the 2010s (CR-I: 2.20–3.20 for CD; 4.11–6.27 for UC)”
> “Regions with slower economic development experienced a delayed onset of rapidly rising incidence, as seen in China and Malaysia, where incidence substantially increased after 2000 (Supplementary Figs. 11a and 12a).”

Source: [Hracs et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12158780/)

<a id="topic-2.2.1.2.1-5"></a>

### Global: incidence increasing worldwide

> “In 2023, the prevalence of ulcerative colitis was estimated to be 5 million cases around the world, and the incidence is increasing worldwide.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

> “UC has evolved into a global burden given its high incidence in developed countries and the substantial increase in incidence in developing countries.”

Source: [Kobayashi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32913180/)

<a id="topic-2.2.1.2.1-6"></a>

### Global: ratio of ulcerative colitis to Crohn's disease by epidemiologic stage

> “We observed a significant difference (P < 0.001) in the UC:CD ratio across the three epidemiologic stages: a median ratio of 3.24:1 in stage 1, decreasing to 1.87:1 in stage 2 and further to 1.54:1 in stage 3 (Supplementary Fig. 17).”
> “On the basis of the assumption that Canada, the United States, most of western Europe, Australia and New Zealand are currently in stage 3, we assigned stage classifications to approximately 65% of our dataset (Supplementary Fig. 16).”

Source: [Hracs et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12158780/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
